Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Pediatric Blood and Cancer

Volumn 57, Issue 7, 2011, Pages 1159-1162

  Ichikawa, Mizuho ^a   Suzuki, Daisuke ^b   Ohshima, Junjiro ^a   Cho, Yuko ^a   Kaneda, Makoto ^c   Iguchi, Akihiro ^a   Ariga, Tadashi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cefozopran; Empirical therapy; Febrile neutropenia; Pediatric cancer; Piperacillin tazobactam

Indexed keywords

CEFOZOPRAN; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS CEREUS; CANCER PATIENT; CANDIDA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORYNEBACTERIUM; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFANT; KLEBSIELLA; MALE; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; MALE; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN;

EID: 80053928537     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23106     Document Type: Article

References (29)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
2. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: Validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 2005; 26S: S123-S127.
3. Viscoli C, Castagnola E, Caniggia M, et al. Italian guidelines for the management of infectious complications in pediatric oncology: Empirical antimicrobial therapy of febrile neutropenia. Oncology 1998; 55: 489-500.
4. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systemic review and meta-analysis. Br Med J 2003; 326: 1111-1120.
5. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
6. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-558.
7. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime+netilmicin or ceftazidime+amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13: 281-287.
8. Jones RN, Pfaller MA, Fuchus PC, et al. Piperacillin/tazobactam (YTR 830) combination: Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis 1989; 12: 489-494.
9. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison. Pediatr Hematol Oncol 2006; 23: 177-186.
10. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43: 447-459.
11. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006; 12: 212-216.
12. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimirob Agents Chemother 1995; 39: 445-452.
13. Abe N, Komatsu M, Iwasaki M, et al. In vitro activity of antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Jpn J Antibiot 2005; 58: 445-451.
14. Ikawa K, Kozumi T, Ikeda K, et al. Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients. Jpn J Antibiot 2009; 62: 435-444.
15. Cherif H, Björkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.
16. Roberts JA, Webb SA, Lipman J. Cefepime versus ceftazidime: Considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007; 29: 117-128.
17. Kebudi R, Görgün O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Peidatr Oncol 2001; 36: 434-441.
18. Lindblad R, Rödjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia-A randomized study comparing meropenem with ceftazidime. Scand J Infect DIs 1998; 30: 237-243.
19. Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 2008; 51: 774-777.
20. Kobayashi R, Sato T, Nakajima M, et al. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol 2009; 31: 270-273.
21. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: Systemic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176-189.
22. Uygun V, Karasu GT, Ogunc D, et al. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: A randomized and open-label study. Pediatr Blood Cancer 2009; 53: 610-614.
23. Le Guyader N, Auvrignon A, Vu-Thien H, et al. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer 2004; 12: 720-724.
24. Aksoylar S, Cetingül N, Kantar M, et al. Meropenem plus amikacin versus piperacillin/tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 2004; 21: 115-123.
25. Nomura K, Morikawa N, Ikawa K, et al. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimirob Chemother 2008; 61: 892-900.
26. King A, Shannon K, Phillips I. Resistance to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 36: 1037-1041.
27. Cao B, Wang H, Sun H, et al. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57: 112-118.
28. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: A comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005; 59: 96-101.
29. Ozkurt Z, Ertek M, Erol S, et al. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31: 870-873.